Grant: Engage Grants Program
Brock University
$25,000.00
Anti-cancer pro-drug therapies: a cure rooted in Daffodils
FY 2016-17
Summary
Cancer is the leading cause of death in Canada and is responsible for 30% of all deaths. It is estimated that 2out of 5 Canadians (45% of men and 42% of women) will develop cancer in their lifetimes, and 1 in 4 of theseindividuals will die of the disease. These are staggering statistics, highlighting the importance of developingeffective anti-cancer therapies.Canadian based Biolyse Pharma located in Niagara, Ontario is one company making a difference in thefight against cancer. As a major producer of injectable Paclitaxel anticancer therapies this company seeks todevelop new lines of cancer fighting drugs that deliver both economic and lifesaving benefits. Thecollaborative research outlined in this proposal will achieve both of these objectives. More specifically, it willlead to the development of anti-cancer pro-drugs and innovative technologies for delivering poorlywater-soluble anti-cancer agents.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
503159-2016
Name nom
Dudding, Travis
Department département
Chemistry
Organization id
22
Institution établissement
Brock University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Anti-cancer pro-drug therapies: a cure rooted in Daffodils
Keyword
NSERC
Application summary
Cancer is the leading cause of death in Canada and is responsible for 30% of all deaths. It is estimated that 2out of 5 Canadians (45% of men and 42% of women) will develop cancer in their lifetimes, and 1 in 4 of theseindividuals will die of the disease. These are staggering statistics, highlighting the importance of developingeffective anti-cancer therapies.Canadian based Biolyse Pharma located in Niagara, Ontario is one company making a difference in thefight against cancer. As a major producer of injectable Paclitaxel anticancer therapies this company seeks todevelop new lines of cancer fighting drugs that deliver both economic and lifesaving benefits. Thecollaborative research outlined in this proposal will achieve both of these objectives. More specifically, it willlead to the development of anti-cancer pro-drugs and innovative technologies for delivering poorlywater-soluble anti-cancer agents.
